

DR REDDYS LABORATORIES LTD

Form 6-K

September 08, 2010

**Table of Contents**

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**Report of Foreign Private Issuer**  
**Pursuant to Rule 13a-16 or 15d-16**  
**of the Securities Exchange Act of 1934**  
**For the Month of August 2010**  
**Commission File Number 1-15182**  
**DR. REDDY S LABORATORIES LIMITED**  
(Name of Registrant)  
**7-1-27, Ameerpet**  
**Hyderabad, Andhra Pradesh 500 016, India**  
**+91-40-23731946**  
(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):  
Not applicable.

**Table of Contents**

- (1) Press Release, Dr Reddy's launches darbepoetin alfa in India under the brand name C<sup>®</sup>esp, August 9, 2010.

**Table of Contents**

**Press Release**

Dr. Reddy's Laboratories Ltd.  
7-1-27 Ameerpet  
Hyderabad 500 016 India

Tel: 91 40 373 1946  
Fax: 91 40 373 1955

[www.drreddys.com](http://www.drreddys.com)

**Dr Reddy's launches darbepoetin alfa in India under the brand name *Cresp*<sup>®</sup>  
World's first generic darbepoetin alfa and the only one in India**

*August 09, 2010, Hyderabad*

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced today the launch of *Cresp*<sup>®</sup> - the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. *Cresp*<sup>®</sup> has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy.

Darbepoetin alfa is a modified version of epoetin alfa (rHuEPO), which is engineered to have a longer half life, increasing (up to 3 times) the time it remains in the blood. This results in a reduced frequency of doses, providing a simpler and more convenient treatment option for patients and physicians as compared to treatment of anemia with epoetin which is the current standard of care in India.

Dr. Reddy's will be launching *Cresp*<sup>®</sup> in both vials and prefilled syringes (PFS).

Commenting on the launch, GV Prasad, Vice-Chairman and CEO, Dr. Reddy's said, "*Cresp*<sup>®</sup> will offer patients in India an improved treatment regimen at affordable pricing. The launch of *Cresp*<sup>®</sup> by Dr. Reddy's is a significant step in redefining the treatment of anemia in India and underscores our commitment to provide affordable and innovative medicines to patients in India."

The launch of *Cresp*<sup>®</sup> is a significant achievement, demonstrating once again our development capabilities in the area of biosimilars. Reditux<sup>™</sup>, launched three years ago, was the first, and still the only biosimilar monoclonal antibody in the world. *Cresp*<sup>®</sup> represents another important first as the only biosimilar Darbepoetin alfa in the world. *Cresp*<sup>®</sup> offers convenient dosing, predictable rise and excellent long term control of Hb, said Cartikeya Reddy, Senior Vice President and Head of Biologics, Dr. Reddy's.

**Notes to the editor:**

Eprex<sup>®</sup> is the originator brand of epoetin marketed by Johnson & Johnson. Eprex is a registered trademark of Johnson & Johnson.

Darbepoetin alfa was developed and launched by Amgen in 2001 under the brand name of Aranesp<sup>®</sup>. Aranesp<sup>®</sup> is a registered trademark of Amgen.

Annual global sales of darbepoetin alfa in 2009 were \$2.65 billion (Source: Amgen 2009 Annual Report).

US sales of darbepoetin alfa \$1.25 billion (Source: Amgen 2009 Annual Report).

In India, epoetin's are a multiproduct market (highly genericized); Eprex being the originator commands a premium price.

*Cresp* has been affordably priced to offer significant monthly savings to patients when compared to Eprex, the originator brand of epoetin marketed by Johnson & Johnson and many of the other biosimilar epoetin therapies available in India.

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Dr. Reddy s currently markets Grafee™ (biosimilar filgrastim) and Reditux™ (biosimilar rituximab) in India and several other countries.

Dr. Reddy s pipeline of biosimilars includes a pegylated molecule in late stage clinical trials, two products in late stage development which are scheduled to enter clinical trials and several others in early stage development.

**Table of Contents**

**Disclaimer**

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

**About Dr. Reddy s**

Established in 1984, Dr. Reddy s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia.

**[www.drreddys.com](http://www.drreddys.com)**

**CONTACT INFORMATION**

**Investors and Financial Analysts:**

Kedar Upadhye at [kedaru@drreddys.com](mailto:kedaru@drreddys.com) or on +91-40-66834297

Raghavender R at [raghavenderr@drreddys.com](mailto:raghavenderr@drreddys.com) or on +91-40-66511529

Milan Kalawadia (USA) at [mkalawadia@drreddys.com](mailto:mkalawadia@drreddys.com) or on +1-9082034931

**Media:**

S Rajan at [rajans@drreddys.com](mailto:rajans@drreddys.com) or on +91-40- 66511725

**Table of Contents**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY S LABORATORIES LIMITED  
(Registrant)

Date: September 8, 2010

By: /s/ Sandeep Poddar  
Name: Sandeep Poddar  
Title: Company Secretary